300878.SZ
Zhejiang Wecome Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 31.63
−5.07%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 225.2M | 225.3M | 351.2M | 519.6M | 532.4M |
| Cost of Revenue | 149.6M | 155.3M | 217.1M | 257.1M | 219.1M |
| Gross Profit | 75.6M | 70.0M | 134.1M | 262.5M | 313.4M |
| Operating Expenses | |||||
| R&D Expense | 8.8M | 9.4M | 14.2M | 42.8M | 39.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 40.6M | 40.7M | 61.1M | 41.2M | 37.4M |
| Selling & Marketing Expense | 93.2M | 106.9M | 200.6M | 208.2M | 193.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 155.0M | 169.5M | 293.9M | 302.6M | 274.9M |
| Cost and Expenses | 304.6M | 324.8M | 511.0M | 559.7M | 494.0M |
| Operating Income (EBIT) | (190.7M) | (201.5M) | (153.7M) | (1.9M) | 64.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (200.5M) | (208.5M) | (158.3M) | (6.7M) | 63.1M |
| Income Tax Expense | 17.6M | 21.3M | (13.4M) | 423.6K | 13.7M |
| Bottom Line | |||||
| Net Income | (215.7M) | (227.3M) | (147.4M) | (9.0M) | 48.8M |
| Earnings from Cont. Ops | (218.2M) | (229.7M) | (144.9M) | (7.1M) | 49.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (215.7M) | (227.3M) | (147.4M) | (9.0M) | 48.8M |
| Per Share | |||||
| Basic EPS | (CN¥1.49) | (CN¥1.57) | (CN¥1.03) | (CN¥0.06) | CN¥0.34 |
| Diluted EPS | (CN¥1.49) | (CN¥1.57) | (CN¥1.03) | (CN¥0.06) | CN¥0.34 |
| Revenue Per Share | CN¥1.55 | CN¥1.56 | CN¥2.45 | CN¥3.48 | CN¥3.71 |
| Shares | |||||
| Basic Shares Outstanding | 145.3M | 144.8M | 143.1M | 149.2M | 143.6M |
| Diluted Shares Outstanding | 145.3M | 144.8M | 143.1M | 149.2M | 143.6M |
| Profitability Metrics | |||||
| EBITDA | — | (137.6M) | (84.1M) | 47.1M | 97.3M |
| D&A | — | 64.0M | 69.7M | 49.0M | 32.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026